Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-319022
Filing Date
2026-07-28
Accepted
2026-07-28 09:22:26
Documents
100
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q alks-20260630.htm   iXBRL 10-Q 3893528
2 EX-31.1 alks-ex31_1.htm EX-31.1 20155
3 EX-31.2 alks-ex31_2.htm EX-31.2 20129
4 EX-32.1 alks-ex32_1.htm EX-32.1 25173
5 GRAPHIC img19669778_0.jpg GRAPHIC 13021
6 GRAPHIC img19669778_1.jpg GRAPHIC 134869
7 GRAPHIC img19669778_2.gif GRAPHIC 120244
8 GRAPHIC img19669778_3.gif GRAPHIC 107826
9 GRAPHIC img19669778_4.gif GRAPHIC 10761
  Complete submission text file 0001193125-26-319022.txt   16621212

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alks-20260630.xsd EX-101.SCH 1769173
104 EXTRACTED XBRL INSTANCE DOCUMENT alks-20260630_htm.xml XML 3433811
Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35299 | Film No.: 261208011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)